Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer

Anticancer Research

Volumn 30, Issue 2, 2010, Pages 375-381

  Landt, Solveig ^a   Jeschke, Sophia ^b   Koeninger, Angela ^a   Thomas, Anke ^c   Heusner, Till ^a   Korlach, Susanne ^c   Ulm, Kurt ^d   Schmidt, Peter ^e   Blohmer, Jens Uwe ^f   Lichtenegger, Werner ^c   Sehouli, Jalid ^c   Kuemmel, Sherko ^g  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f Sankt Gertrauden Hospital   (Germany)

^g KLINIKEN ESSEN MITTE   (Germany)

Author keywords

Cervical carcinoma; CIN; HPV; Tumor M2 pyruvate kinase; Tumor marker

Indexed keywords

PYRUVATE KINASE; TUMOR M2 PYRUVATE KINASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; DIAGNOSTIC VALUE; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; PLASMA; PRIORITY JOURNAL; RECURRENT CANCER; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PYRUVATE KINASE; SERPINS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77950540218     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Mazurek S, Zwerschke W, Jansen-Dürr P and Eigenbrodt E: Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem J 356: 247-256, 2001.
2. Mazurek S, Zwerschke W, Jansen-Dürr P and Eigenbrodt E: Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7. Oncogene 20: 6891-6898, 2001.
3. Zwerschke W, Mazurek S, Massimi P, Banks L, Eigenbrodt E and Jansen-Dürr P: Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci USA 96: 1291-1296, 1999.
4. Eigenbrodt E, Fister P and Reinacher M: New perspectives on carbohydrate metabolism in tumor cells. In: Regulation of Carbohydrate Metabolism. Vol.II. Breitner R (Hrsg): CRC Press, Boca Raton, pp. 141-179, 1985.
5. Mazurek S, Boschek CB, Hugo F and Eigenbrodt E: Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15: 300-308, 2005.
6. Van Veelen CW, Verbiest H, Zülch KJ, van Ketel BA, van der Vlist MJ, Vlug AM, Rijksen G and Staal GE: L-Alpha-alanine inhibition of pyruvate kinase from tumors of the human central nervous system. Cancer Res 39: 4263-4269, 1997.
7. Eigenbrodt E, Basenau D, Holthusen S, Mazurek S and Fischer G: Quantification of tumor type M2 pyruvate kinase (Tu-M2-PK) in human carcinomas. Anticancer Res 17: 3153-3156, 1997.
8. Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H and Kloer HU: Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastrointestinal cancer. Anticancer Res 20: 4965-4968, 2000.
9. Kim CW, Kim JI, Park SH, Han JY, Kim JK, Chung KW and Sun HS: Usefulness of plasma tumor M2-pyruvate kinase in the diagnosis of gastrointestinal cancer. Korean J Gastroenterol 42: 387-393, 2003.
10. Schneider J, Bitterlich N and Schulze G: Improved sensitivity in the diagnosis of gastrointestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK. Anticancer Res 25: 1507-1515, 2005.
11. Schulze G: The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res 20: 4961-4964, 2000.
12. Zhang B, Chen JY, Chen DD, Wang GB and Shen P: Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J Gastroenterol 10: 1643-1646, 2004.
13. Cerwenka H, Aigner R, Bacher H, Werkgartner G, el-Shabrawi A, Quehenberger F and Mischinger HJ: TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res 19: 849-852, 1999.
14. Oremek GM, Eigenbrodt E, Rädle J, Zeuzem S and Seiffert UB: Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer. Anticancer Res 17: 3031-3033,1997.
15. Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P and Gullo L: Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 49: 1149-1155, 2004.
16. Hegele A, Varga Z, Kosche B, Stief T, Heidenreich A and Hofmann R: Pyruvate kinase type tumor M2 in urological malignancies. Urol Int 70: 55-58, 2003.
17. Oremek GM, Sapoutzis N, Kramer W, Bickeböller R and Jonas D: Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma. Anticancer Res 20: 5095-5098, 2000.
18. Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E and Usadel KH: The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res 19: 2599-2602, 1999.
19. Roigas J, Deger S, Schroeder J, Wille A, Turk I, Brux B, Jung K, Schnorr D and Loening SA: Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma. Urol Res 31: 358-362, 2003.
20. Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D and Loening SA: Tumor-M2-Pyruvadrinase beim Nierenzellkarzinom. Untersuchungen im Plasma von Patienten. Urologe 39: 554-556, 2000.
21. Wechsel HW, Petri E, Bichler KH and Feil G: Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res 19: 2583-2590, 1999.
22. Weinberger R, Appel B, Stein A, Metz Y, Neheman A and Barak M: The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma. Eur J Cancer Care 16: 333-337, 2007.
23. Schneider J, Morr H, Velcovsky HG, Weisse G and Eigenbrodt E: Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect Prev 24: 531-535, 2000.
24. Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G and Eigenbrodt E: Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res 22: 311-318, 2002.
25. Schneider J, Velcovsky HG, Morr H, Katz N, Neu K and Eigenbrodt E: Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res 20: 5053-5058, 2000.
26. Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W and Schadendorf D: Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer 117: 825-830, 2005.
27. Ahmed AS, Dew T, Lawton FG, Papadopoulos AJ, Devaja O, Raju KS and Sherwood RA: Tumour M2-PK as a predictor of surgical outcome in ovarian cancer, a prospective cohort study. Eur J Gynaecol Oncol 28: 103-108, 2007.
28. Hoopmann M, Warm M, Mallmann P, Thomas A, Göhring UJ and Schöndorf T: Tumor M2 pyruvate kinase - determination in breast cancer patients receiving trastuzumab therapy. Cancer Lett 187: 223-228, 2002.
29. Lüftner D, Mazurek S, Henschke P, Mesterharm J, Schildhauer S, Geppert R, Wernecke KD and Possinger K: Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer. Anticancer Res 23: 991-997, 2003.
30. Schulze G: HER-2/neu gene product in serum - an oncoprotein in the diagnosis and therapy of breast carcinoma. Anticancer Res 23: 1007-1010, 2003.
31. Thomas A, Fischer T, Winzer HJ, Wegner B, Korlach S, Blohmer JU, Lichtenegger W and Kümmel S: Tumor M2-Pk as predictive factor in primary systemic chemotherapy in breast cancer. J Clin Oncol ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II, 891, 2005.
32. Kaura B, Bagga R and Patel FD: Evaluation of the pyruvate kinase isoenzyme tumor (Tu-M2-PK) as a tumor marker for cervical carcinoma. J Obstet Gynaecol Res 30: 193-196, 2004.
33. Wolter C, Luppa P, Breul J, Fink U, Hanauske AR, Präuer W, Sendler A, Wilhelm O and Neumeier D: Humorale Tumormarker: Praxisorientierte Vorschläge für ihren effizienten Einsatz. Dt Ärztebl 93: A3346-3352, 1996.
34. Pottek T, Müller M, Blum T and Hartmann M: Tu-M2-PK in the blood of testicular and cubital veins in men with testicular cancer. Anticancer Res 20: 5029-5034, 2000.